Literature DB >> 22396170

FGF19 and cancer.

Benjamin C Lin1, Luc R Desnoyers.   

Abstract

Fibroblast growth factors (FGFs) and their cognate receptors, FGF receptors (FGFRs), play critical roles in a variety of normal developmental and physiological processes. Numerous reports support a role for deregulation of FGF-FGFR signaling, whether it is at the ligand and/or receptor level, in tumor development and progression. The FGF19-FGFR4 signaling axis has been implicated in the pathogenesis of several cancers, including hepatocellular carcinomas in mice and potentially in humans. This chapter focuses on recent progress in the understanding of the molecular mechanisms of FGF19 action and its potential involvement in cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22396170     DOI: 10.1007/978-1-4614-0887-1_12

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  27 in total

1.  Loss of FGF21 in diabetic mouse during hepatocellular carcinogenetic transformation.

Authors:  Quan Zhang; Yan Li; Tingting Liang; Xuemian Lu; Xingkai Liu; Chi Zhang; Xin Jiang; Robert C Martin; Mingliang Cheng; Lu Cai
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

2.  A variant of FGF19 for treatment of disorders of cholestasis and bile acid metabolism.

Authors:  Julian R F Walters; Richard N Appleby
Journal:  Ann Transl Med       Date:  2015-05

Review 3.  Fibroblast growth factors 19 and 21 in acute liver damage.

Authors:  Zhao Shan; Gloria Alvarez-Sola; Iker Uriarte; María Arechederra; Maite G Fernández-Barrena; Carmen Berasain; Cynthia Ju; Matías A Avila
Journal:  Ann Transl Med       Date:  2018-06

4.  Mesenchymal stem cell-derived exosomes facilitate nasopharyngeal carcinoma progression.

Authors:  Si Shi; Qicheng Zhang; Yunfei Xia; Bo You; Ying Shan; Lili Bao; Li Li; Yiwen You; Zhifeng Gu
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

5.  The Effect of Molecular Weight, PK, and Valency on Tumor Biodistribution and Efficacy of Antibody-Based Drugs.

Authors:  Ruth Muchekehu; Dingguo Liu; Mark Horn; Lioudmila Campbell; Joselyn Del Rosario; Michael Bacica; Haim Moskowitz; Trina Osothprarop; Anouk Dirksen; Venkata Doppalapudi; Allan Kaspar; Steven R Pirie-Shepherd; Julia Coronella
Journal:  Transl Oncol       Date:  2013-10-01       Impact factor: 4.243

6.  Genome-wide copy number variation pattern analysis and a classification signature for non-small cell lung cancer.

Authors:  Zhe-Wei Qiu; Jia-Hao Bi; Adi F Gazdar; Kai Song
Journal:  Genes Chromosomes Cancer       Date:  2017-05-04       Impact factor: 5.006

7.  FXR Primes the Liver for Intestinal FGF15 Signaling by Transient Induction of β-Klotho.

Authors:  Ting Fu; Young-Chae Kim; Sangwon Byun; Dong-Hyun Kim; Sunmi Seok; Kelly Suino-Powell; H Eric Xu; Byron Kemper; Jongsook Kim Kemper
Journal:  Mol Endocrinol       Date:  2015-10-27

8.  High fibroblast growth factor 19 (FGF19) expression predicts worse prognosis in invasive ductal carcinoma of breast.

Authors:  Abdelbaset Buhmeida; Ashraf Dallol; Adnan Merdad; Jaudah Al-Maghrabi; Mamdooh A Gari; Muhammad M Abu-Elmagd; Adeel G Chaudhary; Adel M Abuzenadah; Taoufik Nedjadi; Eramah Ermiah; Fatima Al-Thubaity; Mohammed H Al-Qahtani
Journal:  Tumour Biol       Date:  2013-11-19

9.  Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors.

Authors:  Wuqing Deng; Xiaojuan Chen; Kaili Jiang; Xiaojuan Song; Minhao Huang; Zheng-Chao Tu; Zhang Zhang; Xiaojing Lin; Raquel Ortega; Adam V Patterson; Jeff B Smaill; Ke Ding; Suming Chen; Yongheng Chen; Xiaoyun Lu
Journal:  ACS Med Chem Lett       Date:  2021-03-22       Impact factor: 4.345

Review 10.  Novel bile acid therapeutics for the treatment of chronic liver diseases.

Authors:  Vinod S Hegade; R Alexander Speight; Rachel E Etherington; David E J Jones
Journal:  Therap Adv Gastroenterol       Date:  2016-02-17       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.